Decentralised Clinical Trials in 2026: What Pharma and Biotech Companies Need to Know
What Decentralised Clinical Trials Actually Are
A decentralised clinical trial is not simply a trial with a website or a remote consent process. The term covers a broad spectrum of approaches that move trial activities — including recruitment, consent, drug delivery, data collection, assessments, and monitoring — away from fixed investigator sites and closer to where patients actually live.
DCTs gained substantial attention during the COVID-19 pandemic, enabling trial activities to be conducted from participants’ homes or local healthcare facilities despite restrictions and lockdowns — and the interest and momentum built during that period has continued well beyond it.
In practice, most trials in 2026 run as hybrid models rather than fully decentralised. A hybrid trial might conduct screening and initial dosing at a clinical site, then shift follow-up assessments and safety monitoring to remote interactions, telehealth visits, and wearable devices. In 2026, decentralised and hybrid trials are becoming the default design choice in many indications, particularly where patient burden of travel is a meaningful barrier to enrollment.
Why Sponsors Are Moving to DCT Design
DCTs address this directly. By bringing the trial to the patient rather than requiring the patient to travel repeatedly to a site, sponsors can access a broader, more geographically diverse population, reduce dropout rates, and improve data completeness. Preliminary results suggest modest improvements in demographic diversity when local pharmacies and mail outreach are incorporated, and some remote monitoring data has shown better patient compliance than equivalent clinic-based data collection.
For sponsors, the other significant driver is timeline. Slow enrollment is one of the most expensive problems in drug development. Anything that expands the eligible patient pool and reduces the friction of participation compresses recruitment timelines — which has direct knock-on effects on trial costs and regulatory submission dates.
Efficient patient recruitment in a decentralised model requires a fundamentally different strategy from traditional site-based recruitment. Digital outreach, patient advocacy partnerships, and community-based screening programmes replace or complement physician referrals, and the pre-screening process needs to be adapted for remote initial interactions.
The Biggest Operational Challenges Right Now
The challenges that most commonly cause problems in practice are:
Technology integration across vendors — sponsors and CROs have been shifting away from stitching together multiple point solutions and instead looking for integrated partners who can combine devices, telehealth, logistics, data, and support into a single coherent stack. Fragmented technology creates data silos, increases validation burden, and complicates monitoring.
Direct-to-patient drug logistics — shipping investigational medicinal products directly to participants’ homes introduces cold chain, customs, labelling, and chain-of-custody challenges that traditional site-based distribution does not. Each country has different requirements for home delivery of clinical trial supplies, and these must be mapped before a global DCT is designed.
Digital equity and access — not all patient populations have equal access to smartphones, reliable internet, or the digital literacy needed to participate in a technology-intensive trial. Designing a DCT that inadvertently excludes the patients most in need of the therapy is both a scientific and an ethical problem.
Remote monitoring and risk-based oversight — clinical trial monitoring in a decentralised model requires a risk-based monitoring plan specifically adapted for remote data review. Traditional 100% source data verification at site is neither practical nor appropriate in most DCT designs. Risk-based monitoring approaches, supported by centralised statistical monitoring, are now the standard — but they require more sophisticated planning and technology than many sponsors have in place.
What Good DCT Planning Looks Like
Sponsors who run successful decentralised or hybrid trials consistently get a few foundational elements right from the start:
DCT-readiness assessment before protocol finalisation — evaluating which trial elements are genuinely suitable for decentralisation based on the indication, patient population, endpoints, and regulatory context, rather than defaulting to full DCT or no DCT without analysis.
Technology vendor selection with validation in mind — every platform used to collect, transmit, or store trial data in a GxP context needs to be validated. Vendor qualification and system validation should be completed before the trial starts, not during it.
Regulatory pre-submission alignment — for pivotal studies with significant DCT elements, engaging with the FDA or EMA in pre-IND or scientific advice meetings to confirm that the proposed approach is acceptable before finalising the protocol avoids costly late-stage redesigns.
Integrated monitoring plan — the risk-based monitoring plan should be designed specifically for the DCT model, identifying the highest-risk data points, defining how central monitoring signals will trigger on-site or remote intervention, and setting clear escalation thresholds.
The Outlook
Medical and pharmaceutical cost trends are forecast to remain elevated into 2026, keeping procurement sharp and shifting more focus to technologies that clearly shorten timelines or prevent costly protocol deviations and dropouts. DCTs, when executed well, deliver on both counts.
The sponsors gaining the most advantage from DCT design in 2026 are those that planned carefully, validated their technology stack, aligned with regulators early, and built patient support infrastructure that matches the ambition of their decentralised protocol. For those still in the planning stage, the opportunity to get this right from the start — rather than retrofitting a traditional protocol mid-study — is significant.